(4-chloro-2-methoxy-3-phenylquinolin-6-yl)-(2-methyl-1H-imidazol-5-yl)-pyrimidin-2-ylmethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (4-chloro-2-methoxy-3-phenylquinolin-6-yl)-(2-methyl-1H-imidazol-5-yl)-pyrimidin-2-ylmethanol
• 化学式: C₂₅H₂₀ClN₅O₂
• 分子量: 457.9
• InChiKey: XLTLVXUDCXIGSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  96.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLES À LIAISON PHÉNYLE DE RAR-GAMMA-T
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015057203A1

  公开（公告）日：2015-04-23

  The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涵盖了Formula I的化合物。其中Formula I中：R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中有定义。该发明还涵盖了一种治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还涵盖了通过给予权利要求1中至少一种化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。
• EP2909193A1
  申请人：——

  公开号：EP2909193A1

  公开（公告）日：2015-08-26
• PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP3057950A1

  公开（公告）日：2016-08-24
• [EN] PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS DE ROR-GAMMA-T DE TYPE QUINOLINYLE À LIAISON PHÉNYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014062667A1

  公开（公告）日：2014-04-24

  The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.